刺激性肠综合征的益生菌:更新的系统审查和元分析与试验序列分析
Ansel Shao Pin Tang1, Jingxuan Quek1, Farisah Sulaimi2
1NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Journal of gastroenterology and hepatology
|March 12, 2026
概括
益生菌可以改善刺激性肠综合征 (IBS) 症状严重程度,但目前的证据需要更多的高功率试验来确认. 需要进一步的研究来确认益处,并解决生活质量改善中的不一致性.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 临床试验 临床试验
背景情况:
- 益生菌对刺激性肠综合征 (IBS) 治疗越来越感兴趣.
- 传统的元分析由于多重性问题而面临局限性.
- 需要对益生菌在IBS中的疗效进行严格的评估.
研究的目的:
- 评估益生菌在缓解IBS症状中的有效性.
- 评估益生菌对IBS生活质量 (IBS-QOL) 的影响.
- 使用试验序列分析 (TSA) 来进行可靠的证据评估.
主要方法:
- 对RCT进行选的Medline,Embase,科学网络和Cochrane.
- 在成年IBS患者中比较益生菌与安慰剂.
- 采用对对进行的元分析,其次是TSA,ROB-2和GRADE评估.
主要成果:
- 益生菌显著改善了IBS症状严重性得分 (IBS-SSS).
- 在IBS-QOL中没有观察到显著的改善.
- 交通安全局表示IBS-SSS的证据规模不足;没有证实徒劳或益处.
- 由于不一致性,证据的确定性较低,尽管大多数研究中偏差风险较低.
结论:
- 根据TSA的发现,建议进行进一步的高功率试验.
- 标准化和异质源的识别对于未来的IBS益生菌研究至关重要.
- 目前的证据表明潜在的症状益处,但缺乏令人信服的生活质量改善.
更多相关视频
相关概念视频
Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Irritable Bowel Syndrome III: Medical and Nursing Management
959
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
959
Drugs for Treatment of Diarrhea-Predominant IBS
832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893


